VIGIL NEUROSCIENCE INC (VIGL) Stock Price & Overview
NASDAQ:VIGL • US92673K1088
Current stock price
The current stock price of VIGL is 8.05 USD. Today VIGL is down by 0%. In the past month the price increased by 0.75%. In the past year, price increased by 170.13%.
VIGL Key Statistics
- Market Cap
- 375.694M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.09
- Dividend Yield
- N/A
VIGL Stock Performance
VIGL Stock Chart
VIGL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to VIGL. When comparing the yearly performance of all stocks, VIGL is one of the better performing stocks in the market, outperforming 98.76% of all stocks.
VIGL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VIGL. While VIGL seems to be doing ok healthwise, there are quite some concerns on its profitability.
VIGL Earnings
VIGL Forecast & Estimates
13 analysts have analysed VIGL and the average price target is 8.16 USD. This implies a price increase of 1.37% is expected in the next year compared to the current price of 8.05.
VIGL Groups
Sector & Classification
VIGL Financial Highlights
Over the last trailing twelve months VIGL reported a non-GAAP Earnings per Share(EPS) of -2.09. The EPS increased by 1.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -80.94% | ||
| ROE | -133.18% | ||
| Debt/Equity | 0 |
VIGL Ownership
VIGL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.8 | 398.492B | ||
| AMGN | AMGEN INC | 16.04 | 198.265B | ||
| GILD | GILEAD SCIENCES INC | 16.4 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.21 | 121.459B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 78.932B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.01 | 42.071B | ||
| INSM | INSMED INC | N/A | 30.073B | ||
| BIIB | BIOGEN INC | 11.29 | 27.136B | ||
| NTRA | NATERA INC | N/A | 26.973B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.95 | 23.353B | ||
| MRNA | MODERNA INC | N/A | 21.086B | ||
| EXAS | EXACT SCIENCES CORP | 340.74 | 19.713B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.84B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VIGL
Company Profile
Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. The company is headquartered in Watertown, Massachusetts and currently employs 69 full-time employees. The company went IPO on 2022-01-07. The firm is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. The company is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The firm is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations.
Company Info
IPO: 2022-01-07
VIGIL NEUROSCIENCE INC
100 Forge Road, Suite 700
Watertown MASSACHUSETTS US
Employees: 69
Phone: 18572544445
VIGIL NEUROSCIENCE INC / VIGL FAQ
What does VIGIL NEUROSCIENCE INC do?
Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. The company is headquartered in Watertown, Massachusetts and currently employs 69 full-time employees. The company went IPO on 2022-01-07. The firm is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. The company is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The firm is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations.
Can you provide the latest stock price for VIGIL NEUROSCIENCE INC?
The current stock price of VIGL is 8.05 USD.
What is the dividend status of VIGIL NEUROSCIENCE INC?
VIGL does not pay a dividend.
What is the ChartMill rating of VIGIL NEUROSCIENCE INC stock?
VIGL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of VIGL stock?
VIGIL NEUROSCIENCE INC (VIGL) has a market capitalization of 375.69M USD. This makes VIGL a Small Cap stock.
What is the ownership structure of VIGIL NEUROSCIENCE INC (VIGL)?
You can find the ownership structure of VIGIL NEUROSCIENCE INC (VIGL) on the Ownership tab.